Onzotrigine – Pharmacology of a Novel NaV1.8 Inhibitor

• Present compound potency, selectivity and mechanism of action
• Discuss translatable models of Nav1.8 target engagement
• Highlight efficacy in model systems: human DRG neurons and NHP microneurography
• Correlate inhibition of action potential firing with target inhibition levels

Speakers:

Bryan Moyer

Senior Vice President - Discovery

Latigo Biotherapeutics, Inc.